Discussion Guide

Talk with your patients about CREON® (pancrelipase) and how it is used to treat EPI

Since EPI can be an embarrassing condition to talk about, patients may be hesitant to give you the full picture of their gastrointestinal symptoms and how they feel.

The discussion guide can help your patients with EPI talk to you about their symptoms, medical history, and their medications. Download the guide and share it with your patients at their next visit.

Download
Discussion Guide
Request patient starter kits, product samples, and more

Request patient starter kits, product samples, and more

Contact a Rep
Use the dosing calculator to help determine the proper dosage of CREON® (pancrelipase)

Determine an appropriate per-meal dose for your patients

Use Dosing Guide

Indications and Important
Safety Information

Indications1

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
    of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
    per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

  1. Reference:
  2. CREON [package insert]. North Chicago, IL: AbbVie Inc.

back to top #tbd